Undisclosed HPV E6 inhibitor / Kovina - LARVOL DELTA

Kovina Therapeutics Awarded $2.3 Million NCI Grant to Advance First-in-Class HPV Cancer Therapy Directly Targeting E6 (Businesswire) - "The award follows Kovina’s recent publication in the Proceedings of the National Academy of Sciences (PNAS) validating direct pharmacologic targeting of HPV E6. The research demonstrated restoration of p53 tumor suppressor activity, selective killing of HPV-positive cancer cells and tumor growth inhibition in HPV-positive preclinical models....The NCI award will support key development activities, including CMC, IND-enabling pharmacology and toxicology, and other studies required to support an Investigational New Drug application."

Financing • Preclinical • Solid Tumor